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Post-translational regulationThe sodium/iodide symporter is an intrinsic membrane protein that actively transports iodide into thyroid
follicular cells. It is a key element in thyroid hormone biosynthesis and in the radiotherapy of thyroid
tumours and their metastases. Sodium/iodide symporter is a very hydrophobic protein that belongs to the
family of sodium/solute symporters. As for many other membrane proteins, particularly mammalian ones,
little is known about its biochemistry and structure. It is predicted to contain 13 transmembrane helices,
with an N-terminus oriented extracellularly. The C-terminal, cytosolic domain contains approximately one
hundred amino acid residues and bears most of the transporter's putative regulatory sites (phosphorylation,
sumoylation, di-acide, di-leucine or PDZ-binding motifs). In this study, we report the establishment of
eukaryotic cell lines stably expressing various human sodium/iodide symporter recombinant proteins, and
the development of a puriﬁcation protocol which allowed us to purify milligram quantities of the human
transporter. The quaternary structure of membrane transporters is considered to be essential for their
function and regulation. Here, the oligomeric state of human sodium/iodide symporter was analysed for the
ﬁrst time using puriﬁed protein, by size exclusion chromatography and light scattering spectroscopy,
revealing that the protein exists mainly as a dimer which is stabilised by a disulﬁde bridge. In addition, the
existence of a sodium/iodide symporter C-terminal fragment interacting with the protein was also
highlighted. We have shown that this fragment exists in various species and cell types, and demonstrated
that it contains the amino-acids [512–643] from the human sodium/iodide symporter protein and, therefore,
the last predicted transmembrane helix. Expression of either the [1–512] truncated domain or the [512–643]
domain alone, as well as co-expression of the two fragments, was performed, and revealed that co-
expression of [1–512] with [512–643] allowed the reconstitution of a functional protein. These ﬁndings
constitute an important step towards an understanding of some of the post-translational mechanisms that
ﬁnely tune iodide accumulation through human sodium/iodide symporter regulation.thylene glycol monododecyl ether; CMV, cytomegalovir
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The sodium/iodide symporter (NIS) is an intrinsic membrane
protein that uses the sodium gradient to actively transport iodide into
thyroid follicular cells, representing a key element in thyroid hormone
biosynthesis [1–3]. Its properties are widely exploited for the
radiotherapy of thyroid tumours and their metastases, and its
expression by gene therapy could broaden further its use in medical
applications [2–5]. The human and rat NIS genes were cloned and
sequenced more than ten years ago and, more-recently, the mouse
equivalent [6–8]. NIS belongs to the family of sodium/solute
symporters, such as the sodium/proline or sodium/glucose sympor-
ters [9]. Human NIS is a 643 amino acid protein, predicted to contain
13 transmembrane helices, with the N-terminus oriented extracellu-
larly and the C-terminus (of nearly one hundred amino-acids) facing
the cytosol [10]. NIS is ﬁnely regulated at the transcriptional and post-
translational level. However, whereas much is known about its
regulation at the transcriptional level, few data are available
concerning its post-translational regulation at the molecular level
[3,5,11–15]. Many membrane proteins, especially transporters, exist
as multimeric complexes [16–18]. Some of these oligomeric forms
serve a function for stability, but in other cases they are also required
for catalytic function. For example, both the sodium bicarbonate co-
transporter and the sodium/proton exchanger are found in oligomeric
states but their functional units aremonomers, whereas theminimum
functional unit for the multidrug EmrE or the calcium-ATPase is a
dimer [19–22]. Many studies have investigated the oligomeric state of
the sodium-dependent neurotransmitter transporters in respect to
their function or their trafﬁcking, and it has been shown that the
oligomeric state is a prerequisite in passing quality control in the
endoplasmic reticulum [23]. In the case of GPCRs (G protein-coupled
receptors), the complexity increases with the formation of hetero-
multimers [24]. The supramolecular assembly of membrane proteins
is therefore an important ﬁeld of study, in acquiring a better
understanding of their regulation. In addition the C-terminal region
of hNIS comprises a rather hydrophilic domain that represents the
longer stretch of amino-acids predicted to lie outside the membrane.
It is, therefore, not surprising to encounter in this region most of the
bioinformatically-predicted or biochemically-proven regulatory sites
of the protein: phosphorylation, sumoylation, di-acid, di-leucine and
PDZ-binding motifs [11,13]. This domain may also be involved in the
symporter protein–protein interactions. A study on hNIS truncated
forms (variants 531X or 515X) associated with iodide uptake
deﬁciency, as well as two studies based on chimeric constructs
between human and murine transporters (rat and mouse), have
suggested a role of the C-terminal fragment in the targeting of the
symporter to the plasma membrane, and/or in its stabilisation [25–
27]. A speciﬁc focus on this domain should therefore bring precious
information concerning NIS post-translational regulation.
In our laboratorieswe have established eukaryotic cell lines stably-
expressing various hNIS recombinant proteins at a relatively high
level (around one percent of the total membrane protein), and
developed a puriﬁcation protocol based on immobilized metal afﬁnity
chromatography (IMAC) and immuno-afﬁnity chromatography using
in-house antibodies. This allowed us to purify, for the ﬁrst time,
milligram quantities of this human transporter. Thus puriﬁed, the
protein exists in different structural forms, which were further
characterised and analysed by size exclusion chromatography (SEC)
and light scattering (LS) spectroscopy, in order to determine the hNIS
oligomeric state. Besides, we have also characterised in detail a C-
terminal fragment of NIS that co-puriﬁes with the full-length protein
expressed in HEK 293 cells. This fragment was found in physiological
situations and in all cell types expressing NIS that we tested. Edman
sequencing allowed us to deﬁne its ﬁrst amino acid residues, showing
that it is constituted of the 131 last amino acid residues of the
transporter, and therefore of the last transmembrane helix. Thepossible origin of the fragment was investigated and is discussed.
Expression of either the N-terminal truncated domain (fragment [1–
512]) or the C-terminal domain (fragment [512–643]) alone, as well
as co-expression of the two fragments, was performed. In each case
the proteins were characterised by immunoﬂuorescence and cell
surface biotinylation experiments in order to investigate their
localisation, and by iodide uptake measurements to study their
functional activity.
The overall analyses revealed important features and highlighted
several interactions which may contribute to the post-translational
mechanisms that ﬁnely tune iodide accumulation through hNIS
regulation.
2. Materials and methods
2.1. Materials
All chemicals were purchased from Sigma-Aldrich, unless other-
wise speciﬁed. Cell culture media and reagents were obtained from
Gibco or Invitrogen. BCA was obtained from Pierce, LDS loading buffer
and electrophoresis MOPS buffer were obtained from Invitrogen;
DDM (reference D310) was purchased from Anatrace and C12E8
(reference 74,680) from Fluka. TetraHis antibody was purchased from
Qiagen, the anti β-tubulin monoclonal antibody (clone D66) from
Sigma-Aldrich, the anti pan cadherin from Anaspec (Fremont, CA,
USA), and ECL plus from Amersham.
2.2. Construction of expression vectors and establishment of
recombinant cell lines
Several human sodium/iodide symporter variants were sought
with i) no Tag (hNIS), ii) a 6-histine tag at the C-terminus (hNIScH),
iii) a FLAG tag (MDYKDDDDK) at the N-terminus and a 6-histine tag at
the C-terminus (hNISnFcH), and iv) a FLAG tag and a 6-histine tag at
the C-terminus (hNIScFH). For this purpose, hNIS gene was ampliﬁed
with the appropriate primers, using a FL*-hNIS/pcDNA3 template
(kindly provided by S. M. Jhiang, Ohio State University, USA). The PCR
products were cloned into pcDNA5-FRT (Invitrogen) by restriction
digest and the absence of unwantedmutations was conﬁrmed by DNA
sequencing.
hNISMDAE (variant with methionine 512 and aspartic 513
residues replaced by alanine and glutamic residues, respectively)
was generated using a protocol based on the QuickChange™ site-
directedmutagenesis protocol of Stratagene. After ampliﬁcation of the
hNIScH plasmid with the primers 5′-GCCCCCAGCTCAGGAGCG-
GAAGCCAGCCGACCCGCCTTAGC-3′ and 5′-GGGTCGGCTGGCTTCCGCT
CCTGAGCTGGGGGCCCTGCTGG-3′, the reactionmix was digested with
DpnI before transformation into Escherichia coli.
hNIS 1–512 (hNIS fragment [1–512] with a 6-histidine tag at the C-
terminus) was constructed using PCR with the following primers: 5′-
CTATAGGCTAGCGCCACCATGGAGGCCGTGGAGACCGGG-3′ and 5′-TAA
CGTGAATTCTTAATGGTGATGGTGATGATGCATTCCTGAGCTGGG
GGCCCTGC-3′. The product was digested with NheI and EcoRI and
cloned into the MCS1 of the pIRES vector (BD Biosciences Clontech).
hNIS 512–643 (hNIS fragment [512–643]) and NIS2P (hNIS fragments
[1–512]-6histidine tag and hNIS fragment [512–643]) were con-
structed using PCR with the following primers: 5′-GGATCCTCTAGAG
CCACCATGGACGCCAGCCGACCCGCC-3′ and 5′-AGGGATGCGGCCGCT-
CAGAGGTTTGTCTCCTGCTGGTC-3′. The products were digested with
XbaI and NotI and cloned into the MCS2 of the pIRES vector and hNIS
1–512, respectively.
Stable cell lines expressing NIS were generated from Flp-In™ 293
(Invitrogen) according to the supplier's protocol. HEK 293-T cells
transitorily expressing NIS were transfected with FuGene (Roche)
with an efﬁciency of approximately 60–70%.
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For culture in wells, HEK 293 cells were grown in Dulbecco's
modiﬁed Eagle's medium (DMEM with glutamine) supplemented
with 10% foetal calf serum, penicillin (100 units/ml) and streptamycin
(100 μg/ml) until approximately 60% cell-conﬂuence was reached, as
detailed in [27]. For protein expression studies, cells were grown in
DMEM supplemented with 10% foetal calf serum, penicillin/strepta-
mycin mix as above (Gibco), and hygromycin (200 μg/ml) until
transfer to the bioreactor SGI (Setric genie Industriel) for 3 l cultures
or Biostat B1 (B. Braun) for 10 l cultures. Inoculationwas performed at
a cell density of 250,000 cells/ml. The culture was usually stopped
after 6 days, corresponding to a plateau in cell density and the
beginning of a decrease in cell viability. Culture conditions were pH
7.3, 30% PO2, 37 °C and 50 rpm stirring. The time-period from frozen
cell stock to cell-collection was generally around 4 weeks, at which
point cells were washed in phosphate saline buffer and frozen
at −80 °C until further use.
2.4. Iodide uptake
Iodide uptake in whole cells was performed according to [27] with
30 μM NaI and 125I. Measurements were made after 5, 15, 30 and
60 min. The radioactivity was measured using a gamma counter
(Packard) and for each set of experiments the value was normalized
to the counts obtained for hNIS at 60 min. For transiently transfected
cells, the same batch of HEK 293 cells was used for all the constructs,
and the uptake was performed 48 h after transfection. For stable cell
lines, values were normalized to the total amount of protein per well.
2.5. Antibodies against NIS
NIS 22R and 23R are in house rat monoclonal antibodies, raised
against hNIS 625–640 peptide. NIS 39 S is an in-house mouse
monoclonal antibody raised against puriﬁed hNIS and targeting a
region located at the C-terminal intracellular domain of the protein
(between amino acid residues 580 and 600). This antibody does not
cross-react with a rat or a mouse NIS. Ab25 anti-mNIS is an afﬁnity-
puriﬁed rabbit polyclonal antibody raised against two peptides of
mouse NIS [27]. This antibody cross-reacts with rat NIS.
2.6. Immuno-ﬂuorescence experiments
Immunoﬂuorescence labelling was performed according to [27]
using NIS 39 S or TetraHis, diluted in PBS, 0.1% BSA at 14.6 μg/ml or
0.1 μg/ml, respectively.
2.7. SDS-PAGE, immunoblot analyses and deglycosylation experiments
Western blot analyses, comparing the effect of different tags on
NIS protein expression, or the different variants, were performed
according to [27] on total cell extract using a 10% or 15% SDS-PAGE,
a RIPA lysing buffer (10 mM tris-HCl, 150 mM NaCl, 1 mM EDTA, 1%
Triton X-100, +/−0.1% SDS, protease inhibitors Complete (Roche)),
a loading buffer containing 2% SDS, 100 mM DTT plus 0.2% beta-
mercaptoethanol, a PVDF membrane, I-Block (Tropix) as a blocking
agent. The antibodies were diluted in PBS, 0.1% BSA and the
Amersham ECL plus enhanced chemiluminescence detection system
or the Pierce SuperSignal West Pico chemiluminescent substrate
system were used for signal detection.
Western blot analyses concerning the puriﬁcation were performed
on a Phast system (GE Healthcare) and detection was performed by an
overnight incubation with the antibodies, and using the anti-mouse or
anti-rat Elite kits from Vectastain. For staining, the colorimetric DAB kit
(Vectastain) was used. SDS-PAGE gels for silver nitrate staining were
obtained from Invitrogen (Novex NuPAGE, 4–12% Bis–tris) and run inMOPS/SDS buffer. For these experiments, samples were prepared in
Invitrogen LDS buffer containing 0% or 5% beta-mercaptoethanol.
Deglycosylation experiments were performed on puriﬁed hNIS
protein using the N-glycosidase F kit from Roche, according to the
supplier's instructions.
2.8. Cell surface biotinylation
Cell surface biotinylation experiments were performed according to
[27]. 48 h after transfection, cells were washed twice with biotinylation
washing buffer (9.6 mMNa2HPO4, 15 mMKH2PO4, 0.1 mMCaCl2, 1 mM
MgCl2, 138 mMNaCl, 2.7 mMKCl). Theywere then incubated for 30 min
at 4 °C in the same buffer supplemented with 1 mg/ml sulfo-NHS-SS-
biotin (Pierce). Remaining free Sulfo-NHS-SS-biotin was removed by
three washes with ice-cold biotinylation washing buffer containing
100 mM glycine. The cells were then lysed for 15 min at 4 °C in lysis
buffer (0.1% SDS, 1% triton X-100, 150 mM NaCl, 1 mM EDTA, 100 mM
tris-HCl pH 7.5, 1 μg/ml aprotinin and 1 μg/ml leupeptin). Lysates were
centrifuged for 15 min at 14,000 g and loaded on streptavidin agarose
beads (Immunopure Immobilized Streptavidin, Pierce). After 1 h
incubation at room temperature, the suspension was centrifuged for
5 min at 14,000 g and the pellet was washed three times in the lysis
buffer. Bound proteins were recovered by the addition of elution buffer
(60 mMtris pH6.8, 2%SDS, 10%Glycerol, 5%β-mercaptoethanol, 0.002%
bromophenol blue), and analysed by western blot.
2.9. Membrane vesicle preparation and protein puriﬁcation
Cells were thawed on ice, suspended in 10 mMHEPES buffer, pH 7.5
containing 250 mM sucrose, 1 mM EDTA and the inhibitor cocktail
Complete (Roche-Applied-Science) (10 ml buffer per g cells (weight
wet)), and disrupted using a cell disrupter (Cell D, Constant system) at a
pressureof 0.3 kbar. After breakage, the lysatewas centrifugedat 1000 g
for 10 min. The supernatantwas then centrifuged at 10,000 g for 10 min
andﬁnally at 370,000 g for 1 hour. Thepelletwas suspended in the same
buffer, to a protein concentration of 20 to 30 mg/ml, asmeasured by the
BCA assay. Membrane vesicleswere aliquoted, frozen in liquid nitrogen,
and stored at−80 °C until further use.
Membrane vesicles were rapidly thawed at 37 °C and diluted in
20 mMHEPES pH7.5 buffer containing 0.5 MNaCl, 10% glycerol, 10 mM
imidazole and protease inhibitors (Complete EDTA free, Roche-Applied-
Science). After centrifugation for 1 h at 370,000 g and 4 °C, the pellet
was suspended in the same buffer to a concentration of 2.2 mg/ml.
Dodecylmaltoside (DDM) was then added dropwise from a 10% (w/v)
stock solution to a ﬁnal concentration of 1%, and the solution was
maintained under magnetic stirring for 30 min at 4 °C. Unsolubilised
material was removed by a 1 h centrifugation at 370,000 g at 4 °C, and
the supernatant was loaded for IMAC using an AKTA FPLC, onto a 5 ml
HiTrap Chelating HP (GE Healthcare) previously loaded with nickel ion,
and equilibrated with a 20 mM HEPES pH 7.5 buffer containing 0.5 M
NaCl, 10 mM imidazole, 0.05% DDM, plus protease inhibitors. After
binding of the protein, the column was washed with the same buffer
containing 40 mM imidazole and the protein eluted at 250 mM
imidazole. Only a small proportion of the transporter eluted at
450 mM imidazole. For immuno-afﬁnity puriﬁcation, the NIS22R
antibody was coupled to a CNBr activated Sepharose 4FF matrix with
an antibody/gel ratio of 2 mg/ml. The 250 mM imidazole fraction
(10 ml) was diluted by a factor of three in 20 mMHEPES buffer, pH 7.5
containing 150 mMNaCl and 0.05%DDM, and incubated overnightwith
10 ml of the antibody coupled gel. The gel was then packed in a column
and washed with the same buffer. Protein elution was performed with
citrate buffer pH3.5 followed byHCl Glycine buffer pH 2.5. The fractions
were immediately neutralised with 1 M tris buffer, pH 8.
At each step after solubilisation, the protein concentration in the
fraction was estimated by UV absorption measurement at
280 nm against the appropriate buffer. In the case of imidazole-
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real contribution of this salt in the fraction. The value of 1.4OD for a 1 g/l
solution and a 1 cm path length cuvette was used throughout the
puriﬁcation and corresponds to the theoretical value for a 0.1% in mass
hNIScH solution, as calculated according to Gill and von Hippel [28].
For experiments with Triton or C12E8, the puriﬁcation protocol
and buffers were the same as described above except that, for
solubilisation, the 1% DDM was replaced by 1% TX-100 or 1% C12E8,
and the 0.05% DDM was replaced in the subsequent buffers by 0.1%
TX-100 or 0.025% C12E8 (around ﬁve times the critical micelle
concentration (CMC) in all cases).
2.10. Size exclusion chromatography and light scattering analyses
SECanalyseswereperformedusinganAgilentHPLCandaTSKG4000
SWXL column fromTosohaas. Thebufferwas a 50 mMphosphate buffer,
pH 6.7, 150 mMNaCl, 0.05% DDM, with a ﬂow rate of 0.5 ml/min. For LS
analyses, the buffer was ﬁltered at 0.1 μm instead of 0.22 μm. Samples
were also concentrated on microcon YM-100 (Millipore) before
injection (around 100 μl). LS analyses were performed with an online
detection chain comprising the Agilent HPLC with its UV detection cell,
the miniDAWN Tristar multi-angle LS detector and the Optilab rEX
differential refractometer from Wyatt technologies. Results were
analysed with the ASTRA program (Version 5.3.1.8) and the speciﬁc
module protein conjugate.Weusedvalues of 0.185 and0.133 ml g−1 for
the protein and DDM dn/dc (speciﬁc refractive index increment),
respectively, and of 1400 and 1.4 ml g−1 cm−1 for UV extinction
coefﬁcients [29].
2.11. Protein sequencing
After puriﬁcation, and concentration on amicroconYM-30, 120 μg of
the immuno-afﬁnity fraction (eluted at pH 3.5) of hNIScHwere injected
onto a TSK G2000 SWXL column for size exclusion chromatography
(phosphate buffer, 0.05% DDM, 1 mM DTT). The peak corresponding to
the free C-terminal fragment was collected, the protein was concen-
trated on a microcon YM-3 and, after incubation with LDS (lauryl
dodecyl sulphate) buffer, was loaded onto a 12% bis–tris SDS-PAGE
(Novex, NuPAGE Invitrogen) in ﬁve wells. After electrophoresis in MES
(4-morpholineethanesulfonic acid) buffer, the proteins were trans-
ferred onto a PVDF membrane (Immobilon PSQ 0.22 μm) and the ﬁve
bands were excised after staining with Coomassie® R-250. The
membrane fragmentswere analysed by Edman sequencing on a Procise
49X HT protein sequencer (Applied Biosystems) connected to a RP-
HPLC for the identiﬁcation of the step-wise released phenylthiohydan-
toin amino acid derivatives. A second sequencing experiment was
performed in similar conditions, except that the size exclusion
chromatography column was a TSK G3000 SWXL.
3. Results
3.1. Expression of hNIS in HEK 293 cells and comparison of the effect of
various tags
hNIS cDNA was expressed in HEK 293 cells. To facilitate
puriﬁcation, tags were added to the protein (6-histidine and/or Flag
tags) at different positions (C and N-terminus), and the effects of
these additions were ﬁrst analysed by measuring iodide uptake in
transiently and stably transfected cells. The data presented in Fig. 1A
show that the addition of a Flag tag at the N-terminal extremity and a
6-histidine tag at the C-terminal end of hNIS protein (hNISnFcH)
resulted in a very signiﬁcant loss of activity compared with wild-type,
hNIScH or hNIScFH (i.e., 40% +/−2% of hNIS iodide uptake for
hNISnFcH stable cell line after 1 h).
Western blot analyses also indicated that the construct hNISnFcH
generated much less NIS protein and that the protein produced wasless-glycosylated (Fig. 1B). In addition, hNIS appeared to be less
aggregated in stable cell lines than in transiently transfected cells.
Immunocytochemistry (Fig. 1C) revealed that the fusion of a Flag
tag at the N-terminus of the transporter resulted in an increased
intracellular form of the protein compared to the other modiﬁcations
or to the wild type. For stable cell lines, the results presented in Fig. 1
were obtained using several independent clones.
Overall, these data showed that the construct hNISnFcH was not
appropriate for our study. In the rest of the report, the stable cell line
generated with the hNIS cDNA encoding for a 6 histidine tag at the
C-terminus of hNIS (hNIScH) was used.
3.2. hNIS expression and puriﬁcation
For puriﬁcation of NIS protein, hNIScH-expressing cells were grown
in suspension. The yield per litre in optimal conditions was 15 g of cells
(wet weight) yielding vesicles containing about 250 mg total mem-
brane proteins. These membrane vesicles were solubilised with DDM
with a yield of approximately 70% for hNIS protein, as estimated by
western blot (Table 1). IMAC with nickel ion was used to capture the
hNIS protein fraction. Loading with 10 mM imidazole and washing
with 40 mM imidazole allowed the elimination of more than 97% of
the contaminating membrane proteins, without any detectable hNIS
loss in the ﬂow-through or washes. The protein was eluted with
250 mM imidazole. At this point, hNIS was still highly contaminated by
other proteins (Fig. 2A, ﬁrst lane). This ﬁrst step of chromatography
was, therefore, followed by an immuno-afﬁnity chromatography with
an in-house antibody NIS22R and an acidic elution at pH 3.5, followed
by an immediate neutralisation. A fraction of the protein eluted only at
lower pH (2.5) and was not used any further as its characterisation
showed more-aggregated forms. As indicated in Table 1, and based on
ﬁve such puriﬁcations, around 1.2 mg of hNIS per 250 mg of
membrane proteins was obtained in the pH 3.5 fraction. Direct
immuno-afﬁnity puriﬁcation reduced the yield.
3.3. Identiﬁcation of the different hNIS species present
Western blot analyses were performed with antibodies recognising
different epitopes on hNIS (NIS23R and NIS39S) and the 6-histidine tag
(TetraHis antibody) (Fig. 2A, lane 3, 4 and 5). The results highlighted
bands thatwere similar to those stainedwith silver nitrate (Fig. 2A, lane
2), suggesting that the proteins in the elution fractions were merely
different forms of hNIS. Themigration pattern obtained bywestern blot
was also identical to what was observed using membrane vesicles,
indicating that these species already existed in the membranes and
werenot artefacts generatedduring the puriﬁcation process (Fig. S1). To
further characterise these different forms, deglycosylation was per-
formed using N-glycosidase F. As shown in Fig. 2B, two of the main
bands shifted towards a unique band of lower molecular weight,
suggesting the co-existence of partially- and fully- (three glycosyla-
tions) glycosylated forms of the protein. This pattern of glycosylation is
similar to observations made using thyroid tissue (healthy or not) [12]
as well as transfected COS cells [10,30], and ﬁts with the detailed
analysis realized by Levy et al. on COS cells [10]. The higher molecular
weight species, likely to correspond to a dimer, appeared also to be
glycosylated. This was in sharp contrast to the 15 kDa band, which did
not seem to be sensitive to N-glycosidase F. To conﬁrm the identity of
the proteins, the different bands on the SDS-PAGE gel stained with
Coomassie blue were excised, subjected to in-gel trypsin digestion and
analysed by mass spectrometry (MALDI-TOF). All analyses identiﬁed
hNIS peptides and indicated that the 15 kDa band contained the
C-terminal peptide, as suggested by western blot analyses (See
Supplementary data S2).
To further the characterisation of this fragment, and as no peptide
corresponding to a potential N-terminus could be detected by mass
spectrometry (MALDI-TOF), we decided to perform Edman sequencing.
Fig. 1. Comparison of the effects of various tags. (A) iodide uptake in whole cells was performed with 30 μM NaI and various incubation times. After washing the cells, the
intracellular content in 125I was determined by gamma counting and, for each set of experiments, this value was normalized to the counts obtained for hNIS at 60 min (set to 100%).
For stable cell lines, the values were previously standardized to the total amount of protein per well. The results plotted represent the average of four and three experiments for
transiently (left) and stably (right) transfected cells, respectively, and with standard error bars. The curves are the corresponding hyperbolic ﬁttings. HEK non-transfected cells: ●,
light grey dotted ﬁt; hNIS: ■, black ﬁt; hNIScH: ▲, light grey ﬁt; hNIScFH: ▼, dark grey ﬁt; hNISnFcH: ♦, dark dotted ﬁt (B).Western blot analyses were conducted on total extracts
(with RIPA buffer) from transiently (left) and stably (right) transfected cells. 20 μg protein was loaded per well and separated on a 10% SDS gel. PVDF membranes were probed with
NIS39S antibody diluted to 1.5 μg/ml and using ECL plus. Molecular weight markers are indicated and the immunoblots shown are representative of at least three independent
experiments. (C) Immunolocalisation of hNIS protein variants with different tags was realized on stably transfected cell lines with the monoclonal antibody NIS39S. The images
shown in the ﬁgure are representative of several independent transfections and multiple ﬁelds on the same slide. The confocal microscope used was a Pascal from Zeiss.
Table 1
hNIScH puriﬁcation yields.
Proteins in
membrane
vesicles1
Solubilized
proteins2
Fraction
after
IMAC3
Fraction 1 after
immuno-afﬁnity
(pH 3.5)
Fraction 2 after
immuno-afﬁnity
(pH 2.5)
Yields 100% 69%±5.3 2.6%
±0.3
0.46%±0.08 0.09%±0.03
250 mg 1.15±0.2 mg
1The protein concentration in membrane vesicles was determined using the BCA assay.
2At each step after solubilization, the protein concentration was estimated by UV
absorption measurement at 280 nm and corrected for imidazole absorption when
necessary. The theoretical value of 1.4 OD for a 1 g/l solution of hNIScH in a 1 cm path
length cuvette was used throughout the puriﬁcation. 3The fraction after IMAC
corresponds to the peak of proteins eluting at 250 mM imidazole. The ﬁgures in the
table represent the average (and standard error) of ﬁve independent puriﬁcations.
Membrane vesicles containing 250 mg protein are usually obtained for samples starting
with about 3 l culture grown in the SGI bioreactor.
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Supplementary data S3). This sequence matches perfectly the protein
sequence derived from hNIS cDNA, starting at position D513. As this
fragment was also revealed by the tetraHis antibody targeting the
6-histidine tag fused to the C-terminal end of the symporter, we
concluded that this 15 kDa protein is, in fact, the last 131 amino acid
residues of theNIS protein. Its theoreticalmolecularweight is 14,067 Da
(15,340 Da with the 6-histidine tag) and it contains the last predicted
transmembrane helix. From the primary structure, no glycosylation is
indeed expected.
3.4. Polydispersity of the puriﬁed transporter
Considering the high degree of heterogeneity of hNIS, illustrated
by the pattern of bands in SDS gels, SEC was used to achieve a better
characterisation and, perhaps, to purify hNIS to a higher degree of
homogeneity. Fig. 3A shows a typical elution proﬁle with UV
Fig. 2. Analysis of the fractions during hNIScH puriﬁcation and characterisation of the glycosylated species. (A) The puriﬁcation fractions after IMAC and after immuno-afﬁnity
chromatographywith the antibody NIS22Rwere analysed on a 4–12% Bis–tris gradient gel run inMOPS buffer (Invitrogen). Lanes 1 and 2 are stainedwith silver nitrate. After transfer
onto a PVDFmembrane, lane 3, 4 and 5 are probed with NIS23R and NIS39S (two antibodies recognising different epitopes on hNIS) and the TetraHis antibody (Qiagen), respectively.
Lane 6 corresponds to the See Blue plus 2 molecular weight marker (Invitrogen). (B) The deglycosylation experiments were performed on puriﬁed hNIScH protein, using N-
Glycosidase F according to the supplier's instructions (Roche). The analysis was performed on a 4–12% Bis–tris gradient gel run in MOPS/SDS buffer (Invitrogen). The proteins were
transferred onto a PVDF membrane which was probed with the TetraHis antibody (Qiagen). Molecular weights are indicated in kDa.
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protein does not elute as a single monodisperse peak, indicating that
puriﬁed hNIS is present in various oligomeric states. To verify that this
heterogeneity was not associated with the puriﬁcation process, and
especially with the acidic elution, the same analyses were performed
just after solubilisation (and also after IMAC). The UV proﬁle could not
be used due to the contribution of the other proteins, however the
western blot pattern was similar with hNIS protein eluting in some
high molecular weight fractions (See Fig. S4). Two other detergents
(Triton X-100 (TX-100) and octaethylene glycol monododecyl ether
(C12E8)) were also used to solubilise and purify hNIS. SDS gel and
western blot analyses revealed a pattern comparable to the oneFig. 3. Size exclusion chromatography analysis of puriﬁed hNIScH and effect of DTT. (A) A
column of puriﬁed hNIScH monitored at 280 nm is shown in the upper panel. In the bottom
Healthcare) with 4–15% gradient gels, a transfer for 15 min on a 0.22 μm Immobilon PSQ m
colorimetric DAB kits from Vectastain were used. Molecular weight marker: Magic Mark (In
hNIScH was performed on 4–12% Bis–tris gradient gels run inMOPS/SDS buffer (Invitrogen),
See Blue Plus 2 (Invitrogen). Note that the proteins migrate with different apparent molecula
on the side by a star.obtained with DDM, with similar levels of monomer, dimer and
higher forms (See Fig. S5).
3.5. Molecular weight determination of the different forms of hNIS by
SEC-LS/UV/RI
The major peak of hNIS eluted during SEC at a MW of
approximately 200–250 kDa, according to soluble MW standards.
This was rather high for a membrane protein of approximately
70 kDa, even with its detergent crown. We therefore coupled SEC to
an online LS analysis system (Wyatt technologies) to determine more
precisely the molecular assemblies present in the puriﬁed samplerepresentative proﬁle of size exclusion chromatography (SEC) on a TSK G4000 SWXL
panel, the western blot analysis of the associated fractions is shown. A Phast system (GE
embrane, and detection with the TetraHis antibody (Qiagen), the anti-mouse and the
vitrogen) (B) Analysis of the effects of the reducing agent DTT on the SEC fractions of
and representative gels stained with silver nitrate are shown. Molecular weight marker:
r weight in the two gel systems. For clarity, the three main bands have been pointed out
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a classical UV detector and a refractometer, in addition to the static LS
module, allowed us to discriminate between the protein and
detergent fractions. The amount of light scattered depends on the
molecular weight, concentration, and speciﬁc refractive index
increment (dn/dc) of the molecule. For soluble proteins, the
concentration is determined by measuring the refractive index and
using a dn/dc of 0.185 ml/g. Contrary to the extinction coefﬁcient (ε),
the dn/dc is almost amino acid-independent and, therefore, protein-
independent. For membrane proteins, or proteins with sugars, the dn/
dc of the complex or molecule is a linear combination of the dn/dc of
the two entities based on their mass proportion in the assembly. It is
therefore necessary to use a third detector (UV) and know the ε of the
different species, as well as the dn/dc of the detergent alone [29,31].
One should also note that in the case of a glycosylated membrane
protein, the three entities cannot be discriminated and the sugar
moiety will be included in the detergent fraction as well as the tightly
bounds lipids. The most effective column was the TSK G4000 SWXL
but, despite its performance, the different oligomeric species could
not be properly separated due, at least partially, to the detergent
crown. LS analysis proﬁles, illustrated by one example in Fig. 4,
indicated clearly the presence of several species with no molecular
mass plateau. However, the peak with a summit at 19.2 in UV
absorbance had a protein molecular weight close to that of a dimer
and the one with a summit at 18.2 corresponded roughly to a
tetramer. By using the postulate that tetramer and monomer never
co-elute, we could calculate the proportion of each species that would
sum to the experimentally calculated molecular weight determined
by the ASTRA software in the range of the grey peak highlighted in
Fig. 4A. The integration of these values gave the proportion of each
oligomeric form. The results of ﬁve analyses on three different
puriﬁcations are summarized in Table 2. As to the precise molecular
mass of the small fragment, this could not be determined as the
detergent micelle contributed too much to the diffusion signal.
Another approach to extract the data from these overlapping species
is to deconvolute the UV signal using Gaussian curves for each species.
This was performedmanually on one analysis (Fig. 4C) and here again,
the integration allowed the determination of each species proportion,
including the small C-terminal fragment, as DDMmicelle interference
with the UV signal is negligible. The results of this analysis on the ‘full
proﬁle’, or restricted to the selected grey peak range in Panel A, are
shown in Table 2. A clear conclusion is that there is almost no
monomer in puriﬁed hNIS fractions. The transporter is found mainlyFig. 4.Molecular mass analyses of hNIScH. Light scattering analysis was performed on the ﬂ
representative of three different experiments. (A) Spectra corresponding to the UV signal at
grey and light grey, respectively. The area between the elution times 18.26 and 20.6 is highlig
The elution area highlighted in Panel A was analysed with the module protein conjugate from
and detergent masses, and results are shown as black dashes, dark grey and light grey lines,
proﬁle of hNIScH elution is shown in black. The curves corresponding to various Gaussian d
dark grey, black long dashes, or light grey long dashes for HMW1, HMW2 and HMW3 respect
grey short dashes for the monomer and dark grey short dashes for the C-terminal fragment. T
almost superimposes with the experimental signal. The areas below these curves were useas dimers and tetramers. One should note at this point that part of the
tetramer is not taken into account in the analyses on the grey peak
range and, therefore, the monomer/dimer ratio is higher for these
cases than for the analysis on the ‘full proﬁle’. According to these data,
it also seems that the trimeric form, if it exists, is minor, but the
analysis becomes less and less reliable in the higher molecular weight
fractions due to a decreasing resolutive power of the size exclusion
column in this molecular range.
3.6. NIS assembly is stabilised by disulﬁde bridges
The presence of the [513–643] fragment in SEC heavy fractions
(Fig. 3A) suggested that it was associated with the full-length
transporter, or with the remaining portion (N-terminal domain) of
the transporter, if this exists as a self-entity. Experiments were,
therefore, performed to test the effects of a reducing agent in the gel
electrophoresis loading buffer, showing a clear difference in the SEC
fractions pattern (Fig. 3B). Without DTT, the [513–643] fragment was
no longer visible in the high molecular weight fractions, indicating
that a disulﬁde bridge was implicated in the interaction. The
proportion of dimer on the gel was also increased in the absence of
reducing agent in the loading buffer, revealing that at least one
disulﬁde bridge also contributed to the full-length transporter
interactions and to the stabilisation of a dimeric species. However,
adding a reducing agent before and/or during SECwas not sufﬁcient to
break the dimers (See Fig. S6).
3.7. The C-terminal fragment is present in NIS from various species and is
not a product of internal translation
Even if it is difﬁcult to estimate the proportions, the amount of the
[513–643] fragment was clearly higher than that of the other faint
intermediate bands distinguishable on silver nitrate-stained gels or
western blot analyses, which most likely represented degradation
products. To check that its presence was not an artefact of our
expression system or that it was not limited to the human protein, the
existence of such a C-terminal fragment was probed in thyroid cells
and in other species. Western blot analyses were performed on
samples obtained from human thyroid (biopsy from a patient with
Graves' disease), from the rat thyroid cell line FRTL5 or from HEK 293
cells stably expressing mouse NIS. In all conditions, a strong 15 kDa
band was visible when a NIS-speciﬁc antibody was used as the probe
(Fig. 5). These data strongly suggest that the expression of the full-ow eluting from the TSK G4000 SWXL after injection of puriﬁed hNIScH. The results are
280 nm, the Rayleigh ratio and the differential refractive index are shown in black, dark
hted in grey (dots) and corresponds to the region analysed in more detail in Panel B. (B)
ASTRA software in order to determine the total molecular mass as well as the protein
respectively. The UV proﬁle is shown in dark continuous line. (C) The UV experimental
istribution associated with the theoretical elution of the different species are shown in
ively, and dark grey long dashes for the tetramer, black short dashes for the dimer, light
he light grey continuous line represents the sum of these multiple Gaussians curves and
d to calculate the proportions of the different species, as stated in Table 2.
Table 2
Proportion of the various oligomeric species of puriﬁed hNIScH.
HMW 1 species HMW 2 species HMW 3 species Tetramer Dimer Monomer C-terminus
ASTRA analysis
18.26–20.6 min range1
26.6% +/−3.3% 64.9% +/−4.2% 8.5% +/−6.5%
UV deconvolution 14–23 min range2 2.5% 8.8% 10.4% 26.2% 32.4% 2.9% 14.5%
UV deconvolution 18.26–20.6 min range3 20.9% 77.9% 1.8%
The proportion (mass percentage) of the various oligomeric species of puriﬁed hNIS was evaluated during size exclusion chromatography. 1The analysis was performed on the
elution range 18.26–20.6 min (highlighted by a grey dotted area in Fig. 4A), using the ASTRA software to evaluate the masses and followed by an integration for the different species.
The results are the average of three different experiments. 2The analyses were performed once on the elution range 14–23 min using a deconvolution of the UV signal as shown in
Fig. 4C, followed by an integration, and attributing the different peaks to the species in concordance with light scattering results (tetramer, dimer or monomer). HMW1, HMW2 and
HMW3 are three species of high molecular weight but ASTRA analysis does not allow a precise determination of their oligomeric nature. 3The same analysis as described for B but on
the elution range 18.26–20.6 min, in order to be closer to the ASTRA analysis.
72 S. Huc-Brandt et al. / Biochimica et Biophysica Acta 1808 (2011) 65–77length NIS protein is accompanied by the presence of a 15 kDa protein
encompassing the C-terminal part of the protein.
However, as the amino acid residue preceding D513 in hNIS is a
methionine residue conserved in the three species studied, we
examined the possibility of an internal translation initiation site. A
hNIS variant was generated to replace the methionine by an alanine
residue. Fig. 6 shows that the 15 kDa protein band was still detectable
in similar proportions. This result demonstrated that an internal
initiation-of-translation is highly unlikely to explain the presence of
this 15 kDa protein species. Altogether, these results suggest that the
additional band observed is the result of cleavage of the full-length
NIS protein.
3.8. Analysis of the potential role of this cleavage on NIS regulation
In order to gain insight into the potential role of the two domains,
each fragment was transiently expressed in HEK 293 cells and the
fragments were also co-expressed. The effects on NIS function, level of
expression and localisation were analysed.
3.8.1. Iodide uptake in cells expressing the [1–512] fragment, the
[512–643] fragment, or both fragments
First, iodide uptake was assessed in the resulting cells. Cells
expressing the [1–512] and [512–643] fragments alone, or no NIS,
accumulated after 1 h 3±0.5%, 4±0.6% and 3.5±0.5% of the iodide
accumulated by the wild-type hNIS, respectively. Conversely, as
shown in Fig. 7, around 9% (8.7±0.9%) of the wild-type activity was
recovered in cells expressing the two fragments (NIS2P). This activityFig. 5. Existence of a C-terminal fragment in various species. Western blot analyses
were conducted onmembrane vesicles from thyroid cells (patient with Graves' disease)
(Lane 1), from HEK 293 cells stably expressing human (Lane 2) or mouse (Lane 3) NIS,
and from the rat thyroid cell line FRTL5 (Lane 4). Proteins were separated on SDS gels
and transferred onto PVDFmembranes. Thesemembranes were probedwith NIS39S for
hNIS (lane 1 and 2) and Ab 25 for mNIS and rNIS (lane 3 and 4).of the split protein is low, but the difference is signiﬁcant (P values
inferior to 0.05 between NIS2P and hNIS 1–512, hNIS 512–643 or HEK
not transfected for 15, 30 and 60 min).
3.8.2. Western blot analysis of cells expressing the [1–512] or [512–643]
fragments, or both fragments
In order to analyse a potential stabilising role of co-expression, and
to investigate if the low activity of the split protein was associated
with a low expression level rather than with a poor intrinsic activity,
western blot analyses of cells expressing the [1–512] or [512–643]
fragments, or both fragments, were performed. As shown in Fig. 8, it
was not possible to detect on western blot analyses, even with femto
ECL, the presence of the [512–643] fragment expressed alone,
whereas co-expression with the [1–512] fragment resulted in a
faint, but clearly visible, band. As for the [1–512] truncated form, a
faint and large band was visible when the protein was expressed
alone or co-expressed with the [512–643] fragment. However, this
expression represents only a small proportion of that of the full-
length protein.
3.8.3. Protein localisation
Membrane proteins require correct targeting to be functional. To
test the localisation of the different NIS fragments, immuno-
cytochemistry was performed but no clear signal was observed.Fig. 6. Effect of theMDAEmutation on hNIS pattern. Western blot analyses were carried
out using total extracts from transiently transfected cells. 40 μg protein were loaded per
well and polypeptides were separated by electrophoresis through a 15% SDS gel. PVDF
membranes were probed with NIS39S diluted at 1.5 μg/ml and using ECL plus.
Molecular weight markers are indicated and the immunoblot shown is representative
of three independent experiments. Lane 1 (HEK NT), non-transfected cells, Lane 2
(hNIS) cells transfected with the wild type hNIS and Lane 3 (hNISMDAE) cells
transfected with the variant without the methionine.
Fig. 7. Iodide uptake. Iodide uptake in transiently transfected, whole cells was performed with 30 μM NaI and various incubation times. After washing the cells, the intracellular
content in 125I was determined by gamma counting, and for each set of experiments this value was normalized to the counts obtained for hNIS at 60 min (set to 100%). The results
plotted represent the average of three experiments with standard error bars with full scale on the left graph and a zoomed scale on the right graph to indicate hNIS2P activity more
clearly. The curves are the corresponding hyperbolic ﬁttings. HEK non-transfected cells□, black dotted ﬁt; hNIS■, black ﬁt; hNIScH ▲, light grey ﬁt; hNIS 1–512▼, light grey dotted
ﬁt; hNIS 512–643 ◊, dark grey dotted ﬁt; hNIS2P ●, dark grey ﬁt.
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all over the cell. Its co-expression did not visibly affect the [1–512]
fragment expression pattern (not shown). To determine more-
precisely the inﬂuence of the [512–643] fragment on [1–512]
fragment targeting to the plasma membrane, a more-quantitative
method (biotinylation) was used. Fig. 9 shows that in both conditions
a proportion of the [1–512] fragment could reach the plasmaFig. 8. Western blot analyses of hNIS 1–512, hNIS 512–643 and hNIS2P variants. Western
blot analyses were conducted on total extracts from transiently transfected cells. 20 μg
proteinwere loadedperwell andpolypeptideswere separated by electrophoresis through
a 15% (upper membrane) or 10% SDS gel (middle membrane). PVDF membranes were
probed with NIS39S diluted at 1.5 μg/ml (upper membrane), TetraHis at 40 ng/ml
(middlemembrane) or antiβ-tubulin at 1 μg/ml (lowermembrane), and using ECL plus.
The lower membrane corresponds to the middle membrane stripped and re-probed
with the anti β-tubulin as a control. Molecular weight markers are indicated in kDa and
the immunoblots shown are representative of three independent experiments.membrane. Quantiﬁcation of the monomeric [1–512] fragment was
performed by densitometry on three different western blot analyses
(corresponding to two different biotinylation experiments) but no
statistically signiﬁcant stabilisation to the plasma membrane was
observed upon co-expression of the [512–643] fragment.
4. Discussion
4.1. A Flag tag at the N-terminal extremity has negative effects on hNIS
expression
In the present study, we generated various isogenic cell lines with
several tags or tag positions, and observed important differences
between them. Indeed, the cell line expressing the Flag tag at the
N-terminal extremity (hNISnFcH) had less activity and produced less
protein (especially in stable cell lines), and western blot analysis
revealed that there was proportionally a lower degree of glycosyla-
tion. Images obtained by confocal microscopy showed, in addition,
more intracellular sequestration of the transporter (Fig. 1C), suggest-
ing a defect in the maturation process. Proteins produced from the
construct hNISnFcH were puriﬁed and a proportion of them were
noted to lack the Flag tag maybe due to a translation ﬂaw or a
proteolytic event. The two populations had a different pattern with
more of the glycosylated form for the subpopulation without the Flag,
conﬁrming that the presence of the Flag interferes with the
maturation process. This effect is not associated with the Flag tag
sequence in itself, as when this tag is added to the C-terminus
(hNIScFH cell line), no deleterious effects are observed. These results
indicate that the presence of a Flag tag at the N-terminal extremity of
NIS impairs its expression. Several studies have reported the tagging
of NIS protein with an N-terminal Flag. In COS-7 cells, the presence of
the N-terminal Flag does not affect iodide uptake as much as in HEK
293 cells [10,26]. However, western blot analysis showed that the
pattern of bands differed greatly compared to the wild-type protein,
with a preponderance of dimers and almost no monomer [10]. The
absence of monomer has also been mentioned by Vadysirisack et al.
[13], in HEK 293 cells. Therefore, the use of such a construct should be
taken with great caution, especially when dealing with post-
translational regulation.
4.2. hNIS can be expressed and puriﬁed in mg amounts
HEK 293 cells transfected with the hNIScH construct acquired the
property of iodide accumulation, indicating that the protein was
correctly folded in this cell line. Uptake assays were carried out after
reconstitution into a lipidic environment to test the function of the
puriﬁed protein, but these assays were not conclusive. However,
Fig. 9. Western blot analyses after cell surface protein biotinylation and immuno-
precipitation. Western blot analyses were performed on samples obtained in cell
surface biotinylation experiments as described in Experimental procedures. 5 μl
aliquots were loaded per well and proteins were separated by electrophoresis through
a 10% SDS gel. PVDF membranes were probed with the TetraHis antibody at 100 ng/ml
and using ECL plus. The immunoblot shown is representative of four independent
experiments.
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[32] have revealed some electrical signals in the presence of iodide
and sodium, suggesting that the puriﬁed transporter is able, at least, to
bind cooperatively these ions. In both cases, work is in progress to
improve the quality of the proteoliposome reconstitution. Western
blot analysis showed a heterogeneous pattern with monomer,
oligomers and at least two levels of glycosylation, as well as a protein
fragment. This pattern is unlikely to be an artefact as it is also observed
in thyroid tissues. After immuno-afﬁnity puriﬁcation hNIS is recov-
ered as a highly enriched fraction: on silver nitrate-stained SDS gels,
the main bands all correspond to NIS molecules with very little, if any,
contaminating proteins. Starting from 15 g cells, it was possible to
obtain around 1.2 mg puriﬁed hNIS (Table 1). Moreover, after SEC, it
was even possible, at the analytical level, to obtain a quasi
homogeneous fraction (Fig. S7).4.3. Characterisation of the hNIS C-terminal fragment
In this report, we have shown that the unexpected band observed
during puriﬁcation of hNIS expressed in HEK 293 cells, is also found in
a cell line of thyroid origin as well as in biopsies of thyroid tissues. In
the literature, this fragment can also be observed in other human
tissues, such as kidney and breast [33,34], in the very few cases where
reports show the low molecular range of western blots. This band has
also been described by Castro et al. in COS7 cells expressing hNIS but,
to date, no data are available regarding its sequence or properties [30].
Edman sequencing enabled us to determine the exact nature of
this fragment. It corresponds to the C-terminal polypeptide of hNIS,
starting from DASRPALAD and encompassing the last 131 amino acid
residues (513–643 in hNIS).
One can note that the region encompassing amino acid residues
508 to 525 (and also the following transmembrane region) is well
conserved between human, rat andmouse (PSSGMD-RPA-AD-FYA are
identical amino-acids), and that a similar C-terminal fragment was
detected in cells expressing the murine NIS.In the human, rat and mouse, a methionine residue precedes the
aspartic acid residue 513 in the full-length NIS protein. An internal
translation initiation site of the C-terminal fragment could, thus, be
envisaged. This phenomenon is, however, very rare in eukaryotes
[35]. In addition, preceding an aspartic acid residue, the methionine
should not have been processed and, therefore, should have been the
ﬁrst amino acid residue identiﬁed by Edman sequencing [36]. Analysis
of putative alternative splicing events on the cloned human DNA
sequence also did not predict such a fragment.
The ﬁnding that the human [512–643] fragment expressed alone
was not detectable by western blot analyses (Fig. 8) constitutes an
additional argument indicating that it is not expressed as a separate
entity but is generated after production and insertion into the
membrane of the full-length protein.
In addition, the fact that we could identify a unique amino acid at
the N-terminal extremity suggests that the [513–643] fragment is not
produced from a longer fragment shortened by an exoprotease, but
rather is generated by a speciﬁc proteolytic cleavage of the
polypeptide chain. We did not detect such a fragment when hNIS
was expressed in E. coli (Fig. S8) suggesting that this mechanism may
not be conserved in prokaryotes, or that the fragment is quickly
degraded following its generation in bacteria.
According to topological models, the localisation of the cleavage
site would imply that this phenomenon occurs intracellularly under
the action of vesicular proteases, or extracellularly if the protein has
reached the plasma membrane. In the latter case, ectoenzymes or
secretory proteases could be involved. Such a speciﬁc proteolysis is
not a rare phenomenon in channels and has already been described
for the sodium phosphate co-transporter, for which it also occurs in an
external loop [37–40].
However, a search in the literature and databases such as MEROPS
(http://www.merops.sanger.ac.uk), did not identify the speciﬁc
protease responsible for the proteolytic cleavage of NIS.
4.4. hNIS is present as different oligomeric forms but mostly as a dimer
Puriﬁed hNIS protein showed an electrophoretic pattern with
dimers and higher oligomeric forms. We checked that this was not an
aggregation due to DDM by using other non-ionic detergents: Triton
X-100 and C12E8. Contrary to many studies, these protocols were
carried out starting from membrane vesicle solubilisation, and led to
the same heterogeneous pattern on western blots as DDM (Fig. S5).
This pattern is, in fact, similar to previous analyses in our laboratory or
in other laboratories in which thyroid tissues, cells or membrane
vesicles are directly solubilised with SDS or LDS in the sample loading
buffer [30,34]. Taken together, this suggests that this heterogeneity is
not linked to the detergent itself but rather to the intrinsic state of
hNIS in the membrane. Moreover, one can note that the western blot
pattern for transiently transfected cells indicates more species with
high oligomeric forms than for the stable cell lines, the patterns of
which resemble the ones obtained for thyroid tissues. It is then
reasonable to assume that the oligomeric state analysed in our HEK
293 stable cell line represents the real state in thyroid and is not
associated with the saturation of the expression system or a defect in
the maturation process.
Since this analysis was performed on denatured material, it was
decided to apply an LS technique to determine absolute molecular
weights of proteins in a more native state [31,41–43]. By using the
molecular extinction coefﬁcient calculated theoretically for NIS we
were able to discriminate the fraction of detergent and protein in
the molecular complexes analysed. This allowed us to conﬁrm the
existence in solution of different forms and to correlate them to the
gel analyses. For hNIS, the main species encountered in solution is
the dimeric form with, nevertheless, a high percentage of tetramer.
For the predominant dimeric species, we found a mass ratio protein/
detergent of around 1.1 and the proportion of detergent decreased to
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solution, the hNIS monomeric species represents less than 10%
(Table 2).
This ﬁnding is in keeping with the data of Eskandri et al. on freeze
fracture electron micrographs of NIS injected oocytes, which
suggested the existence of the transporter as a multimeric form [1].
The structure of the Vibrio parahaemolyticus sodium/galactose
symporter (vSGLT) has been solved recently [44]. Like NIS, this
protein belongs to the sodium solute symporter family and has a
sequence identity of 19% (58% similarity) with the iodide transporter.
In the crystals, the protein assembles as a tightly packed dimer and
this may indeed represent the structural unit of these family
members.
4.5. Some interactions in NIS assemblies are stabilised by a disulﬁde
bridge
The different electrophoretic patterns of hNIS in the presence or
absence of a reducing agent in the loading buffer (Fig. 3B) clearly
indicate that hNIS dimer assembly involves at least one disulﬁde
bridge. However, the reducing agent alone, before and during SEC, is
not able to dissociate dimers into monomers (See Fig. S6). This
indicates that other strong interactions maintain the two subunits
tightly associated together. The strength of these hydrophobic
interactions is also highlighted by the fact that neither LDS nor SDS
in the loading buffer can dissociate them, even in the presence of a
reducing agent, as seen with the existence of dimers or multimers on
SDS-PAGE gels. In addition, SDS-PAGE electrophoresis in reducing
conditions of NIS dimeric species eluted in SEC are mostly dissociated
into monomers, whereas for the fractions corresponding to the
tetrameric form, a signiﬁcant proportion migrates as dimers, strongly
suggesting the existence of two distinct types of interaction (Fig.3).
One could hypothesize that the tetrameric form may be, in fact, a
dimer of dimers as is also assumed for sodium-dependent neuro-
transmitter transporters [23].
The different electrophoretic patterns of hNIS fragment in the
presence or absence of a reducing agent in the loading buffer (Fig. 3B),
as well as its presence in SEC heavy fractions (Fig. 3A) also clearly
suggests that it is associated with the full-length transporter, or with
the remaining portion (N-terminal domain) of the transporter, if this
exists as a self-entity, and that a disulﬁde bridge is implicated in the
interaction.
4.6. hNIS [1–512] and [512–643] fragments are in strong interaction and
can reconstitute a functional transporter
The interactions between the C-terminal and N-terminal domains
have been studied in more details. The co-expression of both
fragments [1–512] and [512–643] in the same cells resulted in the
restoration of iodide uptake, while each fragment expressed sepa-
rately was devoid of activity (Fig. 7). The level of uptake achieved was
only 9% of the wild-type NIS. These results suggest clearly that strong
interactions exist between these two domains, and that they are able
to reconstitute a functional protein. Considering the low level of
expression achievable for both fragments, the reconstituted complex
is highly active and a certain degree of structural ﬂexibility is tolerated
for iodide translocation in the last predicted external loop of hNIS.
This capability to reconstitute a functional transporter through the
co-expression of protein fragments is not unique and has been
described for membrane proteins such as Lac permease [45], the outer
membrane protein OmpA [46], the voltage gated chloride channel
CLC-1 [47], the cytochrome bc1 complex [48], the sodium/glucose co-
transporter [49], the sodium/calcium exchanger [50] or the type II
sodium/phosphate co-transporter [51]. In the case of hNIS, we have
demonstrated that the fragment [512–643] exists in cells at normal
physiological conditions and, therefore, this observation has a higherdegree of biological signiﬁcance. These interactions are strong enough
to be created without the help of a peptidic covalent link and rely
mainly on hydrophobic contacts between helices.
Recently, the structure of the Vibrio parahaemolyticus sodium/
galactose symporter (vSGLT) has been elucidated [44]. This protein
belongs to the sodium solute symporter family and has a sequence
identity of 19% (58% similarity) with NIS. In the crystals, the protein
assembles as a tightly-packed dimer. Helix 13 is in proximity to TM7E,
TM11 and TM12 in the same monomer and to TM3, TM11 and mainly
TM13 in the other monomer. It is possible that similar interactions take
place in NIS. In particular, the last transmembrane segment could be
part of the dimerization interface. Castro et al. [30] clearly demonstrat-
ed the presence of a band around 30 kDa under non-reducing
conditions, when analysing hNIS by western blot. This would suggest
that the disulﬁde bridge implicated in the dimerization could involve
two cysteine residues in this region but not one in the [513–643]
fragment and one on the remaining part of NIS.
The knowledge that the hNIS [512–643] fragment expressed alone
is not visible on western blot analyses, whereas when co-expressed
with the hNIS [1–512] fragment a band is detected, implies that the
two fragments are able to interact and that the [1–512] fragment
stabilises the [512–643] fragment, which may be otherwise quickly
degraded when expressed alone (Fig. 8).
4.7. The C-terminal domain is not absolutely required for NIS targeting
The C-terminal, cytosolic domain bears many potential regulatory
sites including a PDZ protein binding site, di-leucine and di-acid
motifs, and several phosphorylation sites; these sites are all
potentially implicated in protein sorting, membrane or vesicle
targeting and endocytosis. An attractive hypothesis would be that
co-expression of the [512–643] fragment could bring the appropriate
signal and/or protein–protein interactions required for the efﬁcient
targeting of the [1–512] fragment to the plasma membrane.
However, our biotinylation experiments contradict this hypothe-
sis, as a proportion of the [1–512] fragment can reach the plasma
membrane and co-expression of [1–512] and [512–643] does not
signiﬁcantly increase membrane targeting. These results imply that
the C-terminal end of NIS is not absolutely required for membrane
targeting and has no favourable effect at all as a [512–643] fragment.
This conclusion is discrepant with the conclusions drawn by
Pohlenz et al.who reported that the mutant S515X, roughly similar to
our hNIS [1–512] fragment, is not targeted to the plasma membrane
but sequestered inside cells. The lack of absolute requirement of the
PDZ protein binding site in the targeting was already suggested by the
lack of effect, at least in non-polarized cells, of the addition of a
6-histidine tag in the C-terminal part of NIS (Fig.1, [27]). Indeed, this
tag disrupts the PDZ recognition site but does not alter NIS membrane
localisation. Considering all of the data available, we conclude that the
putative regulatory sites present in the C-terminal part of NIS are
probably not crucial, but rather act to ﬁnely-tune protein targeting or
turnover.
In contrast, the presence of the C-terminal part of NIS appears to be
very important for protein stability. When expressed as a truncated
form, the level of expression of the N-terminal domain is low,
suggesting instability. One could postulate that co-expressing the
C-terminal domain would stabilise it. Indeed, the [512–643] fragment
may contribute to the dimerization interface of the transporter and for
some membrane proteins, such as in the sodium-dependent neuro-
transmitter symporter family, for example, the association in multi-
mers is a prerequisite to pass the quality control mechanism in the
endoplasmic reticulum and to reach the plasma membrane [23]. As
discussed in the previous paragraph, the functionality of the split
protein implicates proper interactions of the two domains and these
interactions probably occur early in the maturation process. However,
no stabilising effect was observed in our western blot analyses (Fig. 8),
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[512–643] for stabilisation.
4.8. Possible role of hNIS oligomeric assemblies and NIS cleavage
hNIS is present in cells as various oligomeric forms. It is
acknowledged that the oligomeric state of some membrane proteins
varies to regulate their function or control their interactions with
other proteins. In the sodium-dependent neurotransmitter symporter
family, for example, the association in multimer is a prerequisite to
pass the quality control mechanism in the endoplasmic reticulum in
order to reach the plasma membrane. We know that NIS is highly
regulated at the post-translational level, but no precise data are
available. In light of our results, a parallel can be drawn between NIS
oligomeric states and what is known for neurotransmitter symporters
that also co-transport sodium ion. A change in the equilibrium
between the different forms of hNIS, including the rare monomeric
form, could be a way to directly regulate iodide uptake by modulating
protein targeting to the membrane. The role of oligomerisation in
transport functionality is more controversial and the quaternary
structure seems to play only a modest role in the transport cycle of
bacterial transporters, for example [16]. However, the different
interactions highlighted in this study could modify NIS interactions
with partner proteins and hence its function or subcellular
localisation.
Moreover, the physiological role of the [513–643] fragment is not
yet understood but it is puzzling to ﬁnd such an accumulation, even in
healthy tissues and under physiological conditions.
According to the N-end rule pathway [52,53], and considering that
this fragment starts with an aspartic acid residue, the [513–643]
fragment should be ubiquitinylated and degraded. Its interaction with
higher molecular forms of NIS (including disulﬁde bridge), or its
orientation once in themembrane, may prevent this degradation from
occurring. Due to the absence of an effective antibody recognising the
[1–512] complementary fragment, and to the blurry pattern on the gel
with the different oligomeric and glycosylated forms of NIS, it is
technically difﬁcult to determine whether the [1–512] fragment exists
in physiological conditions and to assess the proportion of monomers
which are, in fact, split monomers. The answer to these questions is
crucial to the elucidation of the role of the [513–643] fragment. At this
stage, several hypotheses can be put forward.
First, NIS cleavagemay be associatedwith the regulation of protein
turnover or stability at the membrane. It may, for example, trigger
endocytosis and degradation of the N-terminal domain.
Second, if the fragment [513–643] accumulates as the N-terminal
part of hNIS disappears, it may compete with monomers to prevent
the formation of full-length dimers. The association of this fragment
might, therefore, play an important role in hNIS quaternary structure
regulation and, indirectly, could control the transporter function.
Third, the cleavage may have a direct effect on NIS catalytic
function. Considering that expressing the NIS in two parts generates
an active transporter, the role of the cleavage cannot be to inactivate
hNIS function. Indeed, with a very low level of expression compared
to that which can be achievedwith the full-length protein (Fig. 9), and
even if iodide uptake is not entirely proportional to the amount of
hNIS protein in the plasma membrane, our data demonstrate that the
split transporters are highly functional. However, a ﬁne tuning of the
activity cannot be excluded. For example, the total activity of
inorganic phosphate transport is lower for the split II sodium/
phosphate co-transporter [51]. However, this reduction is due to the
lower level of protein expression and not to the electrogenic
properties which are very similar in terms of substrate binding, pH
and voltage dependency [51].
Alternatively, the cleavage might have a more speciﬁc functional
role, as previously described for several channels. For example, the
C-terminal domain of the calcium channel CaV1.1, is proteolyticallyprocessed, and interacts non-covalently with the remaining part of
the channel and with the regulatory protein kinase (PKA) and A-
kinase anchoring protein [37]. In the case of the sodium channel ENaC,
processing occurs during the maturation with several proteases
(furin, elastase, plasmin) to release inhibitory tracts [38]. In both
cases, the protein is non functional in the absence of cleavage. Here for
NIS, we know that a ﬂexibility of the last external loop is tolerated for
the function but, in fact, it may even be required. In this case, the
cleavage would not have an inhibitory role, as is most often assumed,
but rather an activating one.
Finally, in membrane protein ﬁelds, proteolytic events can occur to
allow for the release of soluble domains, as in ectodomain shedding
[54,55]. These fragments may then have separate functions. In our
case, the cleaved fragment still has a membrane anchor and could, for
example, link the cytoskeleton and scaffold complexes to the plasma
membrane.
5. Conclusion
In conclusion, we present here an efﬁcient expression system
which allowed, for the ﬁrst time, the production and puriﬁcation of
the human sodium/iodide symporter in mg amounts and in a form
similar to what was observed in thyroid tissues. This enabled us to
better characterise a C-terminal fragment of NIS encompassing the
last putative helix of the transporter and existing as a separate entity,
in humans, mice and rats. This [513–643] fragment is likely to be
generated through a proteolytic cleavage of the full-length protein.
We were also able to show that the protein exists mainly as a dimer
stabilised by a disulﬁde bridge and that the [513–643] fragment is able
to reconstitute with its [1–512] counterpart a functional symporter.
These results already represent an important step towards the
understanding of the protein structural organization and provide
clues as to the possible regulation of its function or localisation. In
particular, the ability to separate (or highly enrich) the different
oligomeric forms by SEC, in association with activity measurements,
will enable us to determine which is the real functional unit.
Further experiments are required to understand the physiological
signiﬁcance of the [513–643] fragment, but the perspective of
controlling this event will then give the opportunity to act on NIS
activity and improve its clinical efﬁciency in the treatment of thyroid
cancers and/or its use in radioiodine gene therapy.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamem.2010.08.013.
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